SCHEMBL21616262

SCHEMBL21616262

Cc1nnc(-c2cccc(Oc3ccc(NC(=O)OC(C)(C)C)c(Cl)c3)c2)o1

nearest known ligand 0.42

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
KDM4E B2RXH2 4/20 0.41
POLB P06746 1/20 0.40
MAPT P10636 4/20 0.39
ALDH1A1 P00352 1/20 0.39
SMN1; SMN2 Q16637 4/20 0.39
MEN1 O00255 2/20 0.39
MAPK1 P28482 2/20 0.39
CCR6 P51684 2/20 0.39
KMT2A Q03164 2/20 0.39
L3MBTL1 Q9Y468 2/20 0.39
HPGD P15428 2/20 0.39
TP53 P04637 2/20 0.39
BRD9 Q9H8M2 1/20 0.39
CCR9 P51686 1/20 0.39
LMNA P02545 2/20 0.38
OPRK1 P41145 1/20 0.38
HTT P42858 1/20 0.38
TDP1 Q9NUW8 1/20 0.38
DGAT1 O75907 1/20 0.37
MAPK14 Q16539 1/20 0.37

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL30203153 1.00 KDM4E (0.41) KDM4EPOLBMAPTALDH1A1SMN1; SMN2
SCHEMBL30203277 0.89 CYP17A1 (0.42) KDM4EPOLBMAPTALDH1A1SMN1; SMN2
SCHEMBL23368213 0.89 CYP17A1 (0.42) KDM4EPOLBMAPTALDH1A1SMN1; SMN2
SCHEMBL23355371 0.88 KDM4E (0.45) KDM4EPOLBMAPTSMN1; SMN2MEN1
SCHEMBL23355365 0.77 L3MBTL1 (0.51) KDM4EMAPTALDH1A1SMN1; SMN2MEN1
SCHEMBL24926621 0.77 MAPT (0.41) KDM4EPOLBMAPTALDH1A1SMN1; SMN2
SCHEMBL30203143 0.77 MAPT (0.41) KDM4EPOLBMAPTALDH1A1SMN1; SMN2
SCHEMBL28526784 0.77 SMN1; SMN2 (0.38) KDM4EMAPTALDH1A1SMN1; SMN2MEN1
SCHEMBL23355373 0.76 KDM4E (0.45) KDM4EPOLBMAPTALDH1A1SMN1; SMN2
SCHEMBL23368172 0.76 MAPT (0.43) KDM4EMAPTALDH1A1SMN1; SMN2MEN1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230025510-A1 BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVES DAIICHI SANKYO COMPANY, LIMITED (JP) 2023-01-26 US disclosed
EP-3822263-A1 BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVE Daiichi Sankyo Company, Limited (JP) 2021-05-19 EP disclosed
CN-112334460-A Biaryl ether type quinazoline derivative 第一三共株式会社 2021-02-05 CN disclosed
WO-2020009156-A1 BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVE 第一三共株式会社 2020-01-09 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20230025510-A1 BIARYL ETHER-TYPE QUINAZOLINE DERIVATIVES ERBB2, EGFR, ERBB3 KDM4E 2631/4885POLB 2880/4885MAPT 4074/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.